Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05955183 | Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers.. | PHASE1 | COMPLETED | 38 | — | — | Jul 27, 2023 | Dec 4, 2023 | Dec 8, 2023 | 1 | United States |
The safety and the tolerability after single and multiple doses of AZD5055 in healthy Japanese and Chinese participants will be evaluated.
| Arm | Type | Description |
|---|---|---|
| AZD5055 | ACTIVE_COMPARATOR | Participants will orally receive AZD5055. |
| Placebo | PLACEBO_COMPARATOR | Participants will orally receive placebo. |
| Name | Type | Description |
|---|---|---|
| AZD5055 | DRUG | AZD5055 will be given orally to randomized participants as per the arm they are assigned. |
| Placebo | DRUG | Placebo will be given orally to randomized participants as per the arm they are assigned. |
Inclusion Criteria: * For Chinese subjects only: 1. Participant was born in greater China, including Hong Kong, Macau, and Taiwan. 2. Participant has 2 Chinese biological parents and 4 Chinese grandparents as confirmed by interview. 3. Participant did not live outside of greater China for mo...